Arkolith/Insider Trading/FLXN/Form 4

Clayman Michael D.

President and CEO, DirectorFlexion Therapeutics Inc (FLXN) · full profile →Form 4 · filed Nov 19, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
13
4 non-derivative · 9 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 19, 2021Disposed to issuer(D)335K$8.50$2.9M0
Nov 19, 2021Disposed to issuer(D)374K$8.50$3.2M0
Nov 19, 2021Disposed to issuer(D)25K$8.50$209K0
Nov 19, 2021Disposed to issuer(D)389K$8.50$3.3M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 19, 2021Disposed to issuer(D)175K——0
Nov 19, 2021Disposed to issuer(D)117K——0
Nov 19, 2021Disposed to issuer(D)290K——0
Nov 19, 2021Disposed to issuer(D)185K——0
Nov 19, 2021Disposed to issuer(D)106K——0
Nov 19, 2021Disposed to issuer(D)155K——0
Nov 19, 2021Disposed to issuer(D)110K——0
Nov 19, 2021Disposed to issuer(D)200K——0
Nov 19, 2021Disposed to issuer(D)137K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-21-065703) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML